S. pyogenes

Recombinant Cas9-based fusion with three NLS expressed by E.coli

PE7 is a fusion protein of the small RNA-binding protein La to the prime editor. Research indicates that PE7 has demonstrated substantial improvements in intended editing efficiencies across various cell lines and genomic loci compared to previous versions like PEmax. This development holds promise for a wide range of applications in both basic research and therapeutic settings.

S. pyogenes

Recombinant Cas9-based fusion with double-ended NLS expressed by E.coli

PE2 is a revolutionary genome editing technology that allows for precise genetic modifications with minimal unintended effects. It integrates a Cas9-nickase fusion protein with a reverse transcriptase and a prime-editing guide RNA (pegRNA), enabling flexible editing capabilities.PE 2 represents a cutting-edge development in genome editing technology, offering significant advantages over traditional methods in terms of accuracy and versatility.​

S. pyogenes

Recombinant Cas9-based fusion with three NLS expressed by E.coli

PE6b is a variant of the prime editor protein specifically designed for genome editing in living cells. It enhances the efficiency of genome edits compared to earlier versions of prime editors. Notably, editors like PE6b are smaller in size, allowing for more efficient delivery when used in medical and therapeutic applications.

S. pyogenes

Recombinant Cas9-based fusion with three NLS expressed by E.coli

PE6d is designed to optimize the efficiency of prime editing by altering certain components of the prime editor framework. It incorporates elements that minimize the chances of errors and maximize successful genomic edits across various cell types. This improvement results in enhanced editing accuracy and reduced byproducts, such as unintended indels.

S. pyogenes

Recombinant Cas9-based fusion with three NLS expressed by E.coli

PEmax is an improved version of PE2 with additional NLS and improved nCas9 domain, facilitating precise genome editing without the need for double-stranded DNA breaks. It significantly increases editing efficiency and accuracy compared to earlier systems and allows for a broader range of base conversions and edits within the genome design

S. pyogenes

Recombinant Cas9-based fusion with three NLS expressed by E.coli

PEmax RNase deletion involves modifications to the PEmax enzyme aimed at eliminating unwanted RNase activity, thus enhancing its stability and specificity. This advancement allows for more efficient target editing by minimizing the degradation of RNA components involved in the editing process, further improving the overall performance of the prime editing protocol.

S. pyogenes

Recombinant Cas9-based fusion with three NLS expressed by E.coli

PE6C focuses on enhancing the performance of prime editing in transgenic rice plants. This specific variant of the prime editing technology is tailored to address the challenges of genetic improvement in crops, contributing to enhanced editing precision and efficiency in agricultural applications. The effectiveness of PE6c stems from its design improvements that enable it to facilitate targeted insertions and modifications in plant genomes.

S. pyogenes

Recombinant Cas9-based fusion with double-ended NLS expressed by E.coli

ABE8e is an innovative adenine base editor designed to enable precise genetic modifications by converting A-T base pairs to G-C base pairs without introducing double-stranded breaks or requiring donor DNA templates.​ ABE8e contains eight additional mutations in the TadA domain, augments the effectiveness and applicability of adenine base editing.

S. pyogenes

10.0 mg/ml

GenCRISPR™ Ultra NLS-Cas9-GMP is utilized for CRISPR gene editing applications. It is manufactured in compliance with ISO 13485 and GMP quality management system standards and with stringent process controls and complete documentation records. This product is a ideal choice for most CRISPR gene editing applications where high editing efficiency is preferred.

S. pyogenes

10.0 mg/ml

GenCRISPR™ Ultra eSpCas9-2NLS-GMP is utilized for CRISPR gene editing applications. The Cas9 nuclease forms a stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component. With the help of two nuclear localization signals (NLS) expressed with the Cas9 nuclease, the RNP complex enters the nucleus and cleaves target gene. When compared with a plasmid-based delivery system, the RNP delivery system has been observed to increase the on-target gene editing efficiency and decrease off-target effects.

S. pyogenes

10.0 mg/mL

GenCRISPR™ Ultra NLS-Cas9-basic GMP is utilized for CRISPR gene editing applications. The Cas9 nuclease forms a stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component. With the help of nuclear localization signal (NLS) expressed with the Cas9 nuclease, the RNP complex enters the nucleus and cleaves the target gene. When compared with a plasmid-based delivery system, the RNP delivery system has been observed to increase the on-target gene editing efficiency and decrease off-target effects.

S. pyogenes

10.0 mg/ml

GenCRISPR™ Ultra eSpCas9-2NLS-basic GMP is utilized for CRISPR gene editing applications. The Cas9 nuclease forms a stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component. With the help of two nuclear localization signals (NLS) expressed with the Cas9 nuclease, the RNP complex enters the nucleus and cleaves target gene. When compared with a plasmid-based delivery system, the RNP delivery system has been observed to increase the on-target gene editing efficiency and decrease off-target effects.